TGF-β inhibitors offer potential antifibrotic and anticancer therapeutic benefits for the treatment of cardiac fibrosis and cancer based on available clinical data.
Targeting TGF-β signaling pathways represents a promising therapeutic strategy for the treatment of both cardiac fibrosis and cancer.
evidence regarding antifibrotic and anticancer actions of TGF-β inhibitors. In addition, we also present available clinical data on therapy based on inhibiting TGF-β signaling for the treatment of cancers and cardiac fibrosis.
Parichatikanond et al. (2020) studied this question. TGF-β inhibitors offer potential antifibrotic and anticancer therapeutic benefits for the treatment of cardiac fibrosis and cancer based on available clinical data.